Shares of Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) advanced after the company said the U.S. Federal Drug Administration (FDA) has lifted a hold on the clinical study of its BPX-501 T-cell therapy.
The firm focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Its stock climbed 20% to US$8.16 in pre-market trading.
Amend study protocols
The decision by the FDA was made after the company agreed to amend study protocols, Bellicum said in a statement.